Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

City of Hope researchers presented compelling real-world evidence and novel combination therapies at the 2025 ASCO Annual Meeting, with findings that could reshape treatment approaches for breast, colorectal, renal, and prostate cancers.

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Podcast

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

“Patients are counting on us, and this remains the best time to be involved in cancer research,” W. Kimryn Rathmell said to The Cancer Letter.

June 04, 2025

Vol.51 No.21

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.

May 30, 2025

Vol.51 No.21

By Claire Marie Porter

Clinical

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

The American Society of Clinical Oncology and Google Cloud have developed a tool called the ASCO Guidelines Assistant to help oncologists parse through and interpret clinical practice guidelines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

Podcast The Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

May 16, 2025

Vol.51 No.19

By Katie Goldberg

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

YOU MAY BE INTERESTED IN

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Renew today!

Subscriber content

Never miss an issue!

Login

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

YOU MAY BE INTERESTED IN

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan AfricaWith help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”